Fampridin Medical Valley (Fampridine 10 mg)
Prolonged-release tablet for improving walking ability in multiple sclerosis
Fampridin Medical Valley contains fampridine 10 mg as prolonged-release tablets. It is a potassium channel blocker prescribed to improve walking ability in adult patients with multiple sclerosis (MS) who have walking disability. Fampridine works by enhancing nerve signal conduction along demyelinated nerve fibres. It is taken as one tablet twice daily, approximately 12 hours apart. Treatment response should be evaluated after 2 weeks using a timed walking test, and the medicine should be discontinued if no improvement is observed.
Quick Facts
Key Takeaways
- Fampridin Medical Valley is a prescription medicine containing fampridine 10 mg, used to improve walking speed in adults with multiple sclerosis who have walking disability.
- Take one tablet twice daily, 12 hours apart. Never exceed two tablets in 24 hours, as higher doses significantly increase the risk of seizures.
- Kidney function must be checked before starting treatment, as fampridine is primarily eliminated through the kidneys and impaired function increases side effect risk.
- Walking improvement should be assessed within the first 2 weeks. If no benefit is seen, treatment should be stopped.
- The most serious potential side effect is seizures. The medicine is contraindicated in patients with a history of seizures or epilepsy.
What Is Fampridin Medical Valley and What Is It Used For?
Fampridin Medical Valley belongs to the pharmacological class of potassium channel blockers. Its active ingredient, fampridine (also known as 4-aminopyridine or dalfampridine in the United States), works by blocking voltage-gated potassium channels on the surface of nerve fibres. In patients with multiple sclerosis, the insulating myelin sheath around nerve fibres becomes damaged through a process called demyelination. This damage exposes potassium channels that would normally be covered, leading to the leakage of ionic current and impaired nerve signal transmission.
By blocking these exposed potassium channels, fampridine reduces the leakage of ionic current, which prolongs repolarisation and enhances the formation of action potentials in demyelinated axons. This improved nerve conduction can translate into measurable improvements in walking ability for patients with MS-related walking disability. The therapeutic effect is specific to demyelinated nerves, which explains why only a proportion of MS patients respond to the treatment.
The medicine is specifically indicated for the improvement of walking in adult patients with multiple sclerosis who have walking disability, defined as an Expanded Disability Status Scale (EDSS) score of 4 to 7. Clinical trials have demonstrated that approximately 35-43% of patients experience a clinically meaningful improvement in walking speed, as measured by the Timed 25-Foot Walk (T25FW) test. These patients, known as "responders," typically show a consistent improvement in walking speed of at least 20% compared to baseline.
Fampridin Medical Valley is a generic formulation that is bioequivalent to the original brand product Fampyra (marketed in Europe) and Ampyra (marketed in the United States). The prolonged-release formulation is critical for maintaining stable plasma levels throughout the day and reducing the risk of concentration-dependent side effects, particularly seizures. The tablet must not be crushed, split, or chewed, as this would destroy the modified-release mechanism and potentially lead to dangerously high peak concentrations.
It is important to understand that fampridine does not treat the underlying disease process of multiple sclerosis. It is a symptomatic treatment that can improve nerve conduction in already damaged nerve fibres. It is typically used alongside disease-modifying therapies (DMTs) that target the immune-mediated damage to myelin. The combination of a DMT to slow disease progression and fampridine to improve existing symptoms represents a comprehensive approach to managing walking disability in MS.
What Should You Know Before Taking Fampridin Medical Valley?
Before prescribing Fampridin Medical Valley, your healthcare provider will conduct a thorough medical assessment to ensure the medicine is safe for you. Several important contraindications and precautions must be considered. Understanding these factors is essential for safe and effective use of this medication.
Contraindications
You must not take Fampridin Medical Valley if any of the following apply to you:
- Hypersensitivity: If you are allergic to fampridine or any of the excipients in the tablet.
- Seizures or epilepsy: If you have a current or previous history of seizures (epileptic fits). Fampridine lowers the seizure threshold, and its use in patients with seizure history carries an unacceptable risk of provoking convulsions.
- Renal impairment: If you have mild, moderate, or severe renal impairment (creatinine clearance less than 80 ml/min). Since approximately 90% of fampridine is eliminated unchanged through the kidneys, impaired renal function leads to elevated plasma concentrations and a significantly increased risk of seizures.
- Concurrent use of other fampridine-containing products: You must not take any other medicines containing fampridine (4-aminopyridine) simultaneously, including compounded formulations, as this increases the risk of overdose and seizures.
Warnings and Precautions
Your doctor should exercise particular caution and monitor you more closely if you have any of the following conditions or circumstances:
- Cardiac arrhythmias or conduction disorders: Fampridine may affect cardiac electrophysiology. Patients with pre-existing cardiac rhythm disturbances should be carefully monitored, particularly during treatment initiation.
- Immune-mediated reactions: Hypersensitivity and anaphylactic reactions have been reported, including urticaria, angioedema, and dyspnoea. These may occur at any time during treatment, even in patients who have previously tolerated the medicine.
- Infections: Urinary tract infections are common during fampridine treatment. If you develop symptoms such as painful or frequent urination, fever, or cloudy urine, contact your healthcare provider promptly.
- Elderly patients: Renal function naturally declines with age. Your doctor may need to perform regular kidney function tests to ensure that fampridine levels remain within safe limits. Dose adjustments are not possible with the available formulation, so the medicine may need to be discontinued if renal function deteriorates.
- Dizziness and balance problems: Fampridine can cause dizziness and balance disturbances, which may increase the risk of falls. This is particularly relevant for MS patients who already have impaired balance and mobility.
Never take more than one tablet (10 mg) at a time, and never take more than two tablets (20 mg) in a 24-hour period. The risk of seizures is strongly dose-dependent, and overdose with fampridine can cause status epilepticus, which is a life-threatening emergency. If you accidentally take too much, seek immediate medical attention. A minimum interval of 12 hours must be maintained between doses.
Pregnancy and Breastfeeding
There is limited data on the use of fampridine during pregnancy in humans. Animal studies have shown reproductive toxicity at doses higher than the recommended human dose, including decreased pup viability and increased skeletal variations. As a precautionary measure, fampridine should not be used during pregnancy unless clearly necessary and the potential benefit justifies the potential risk to the foetus.
It is not known whether fampridine is excreted in human breast milk. Animal studies have shown that fampridine is excreted in milk. A decision must be made whether to discontinue breastfeeding or to discontinue the medicine, taking into account the benefit of breastfeeding for the child and the benefit of therapy for the mother. Your healthcare provider can help you weigh these considerations.
If you are planning to become pregnant, are currently pregnant, or are breastfeeding, discuss this with your doctor before starting or continuing treatment with Fampridin Medical Valley. Alternative management strategies for walking disability may be considered during pregnancy and breastfeeding, such as physiotherapy and assistive devices.
How Does Fampridin Medical Valley Interact with Other Drugs?
Understanding drug interactions is essential for the safe use of fampridine. Because the medicine is primarily eliminated unchanged through the kidneys, most clinically significant interactions involve drugs that affect renal excretion rather than hepatic metabolism. Fampridine is a substrate of the organic cation transporter 2 (OCT2), which plays a key role in its renal tubular secretion.
Major Interactions
| Interacting Drug | Mechanism | Clinical Effect | Recommendation |
|---|---|---|---|
| Other fampridine products | Additive exposure | Greatly increased seizure risk | Contraindicated — never combine |
| Cimetidine | OCT2 inhibition | Increased fampridine plasma levels | Avoid concomitant use |
| Other OCT2 inhibitors (e.g. quinidine) | OCT2 inhibition | Potential increase in fampridine exposure | Avoid concomitant use |
The combination of fampridine with any other product containing fampridine or 4-aminopyridine is strictly contraindicated. This includes compounded (pharmacy-prepared) formulations of 4-aminopyridine that may be available in some countries. Using two fampridine-containing products simultaneously can lead to dangerous plasma concentrations and a markedly increased risk of seizures.
Cimetidine, an H2-receptor antagonist used for acid reflux and peptic ulcers, is a potent inhibitor of OCT2. Co-administration with cimetidine has been shown to increase fampridine exposure by approximately 22%. Although this increase may seem modest, given the narrow therapeutic window of fampridine and the dose-dependent risk of seizures, concomitant use with cimetidine is not recommended.
Other Interactions to Consider
| Interacting Drug | Mechanism | Clinical Effect | Recommendation |
|---|---|---|---|
| OCT2 substrates (metformin, carvedilol, propranolol) | Competition for OCT2 transport | Potential altered excretion of either drug | Use with caution; monitor |
| Baclofen | Pharmacodynamic — both affect CNS | Increased risk of dizziness, balance disorders | Monitor; dose adjustment of baclofen may be needed |
| Interferon beta | No pharmacokinetic interaction | No significant interaction observed | Safe to combine |
| Glatiramer acetate | No pharmacokinetic interaction | No significant interaction observed | Safe to combine |
Fampridine itself is also an inhibitor of OCT2 at therapeutic concentrations. This means it may potentially affect the renal elimination of other drugs that are substrates of OCT2, including metformin (used for type 2 diabetes), carvedilol and propranolol (used for heart conditions and high blood pressure). If you are taking any of these medicines, your doctor should monitor you for any changes in their effectiveness or side effects.
Clinical studies have shown no significant pharmacokinetic interactions between fampridine and common MS disease-modifying therapies, including interferon beta-1a, interferon beta-1b, and glatiramer acetate. Fampridine can generally be used safely alongside these treatments. However, always inform your healthcare provider about all medicines you are taking, including over-the-counter products, herbal remedies, and supplements.
What Is the Correct Dosage of Fampridin Medical Valley?
Fampridin Medical Valley has a fixed dosing regimen that applies to all eligible adult patients. Unlike many medications, the dose cannot be titrated up or down because the medicine is only available as a 10 mg prolonged-release tablet that must not be divided. Strict adherence to the dosing schedule is essential to maintain therapeutic plasma levels while minimising the risk of seizures.
Adults
Standard Adult Dose
Dose: 10 mg (one tablet) twice daily
Schedule: One tablet in the morning and one tablet in the evening, approximately 12 hours apart
Maximum daily dose: 20 mg (two tablets in 24 hours)
Administration: Swallow whole with a glass of water. May be taken with or without food (although taking without food is preferred to avoid increased peak levels).
The 12-hour interval between doses is critical. This spacing ensures that plasma concentrations remain within the therapeutic range while avoiding excessive peak levels. Taking two tablets too close together can produce dangerously high concentrations and increase the risk of seizures. If you find it difficult to maintain a 12-hour schedule, discuss timing strategies with your pharmacist or doctor.
The prolonged-release formulation releases fampridine gradually over several hours, creating a smoother pharmacokinetic profile compared to immediate-release formulations. Peak plasma concentrations are typically reached within 3 to 4 hours after ingestion. The elimination half-life is approximately 6 hours, which supports twice-daily dosing.
Your doctor should assess the benefit of treatment within the first 2 weeks, typically using a timed walking test such as the Timed 25-Foot Walk (T25FW). If no improvement in walking speed is observed during this initial trial period, fampridine should be discontinued. Approximately 35-43% of patients are classified as "responders." Periodic reassessment of treatment benefit is recommended, for example every 6 months.
Children and Adolescents
Paediatric Use
Fampridin Medical Valley is not recommended for use in children and adolescents under 18 years of age. There are no clinical data on the safety or efficacy of fampridine in this age group. The indication (walking disability in MS) is extremely rare in the paediatric population.
Elderly Patients
Elderly Dose Considerations
Dose: No formal dose adjustment, but kidney function must be checked before starting treatment.
Renal function declines physiologically with age. Before initiating treatment in elderly patients, creatinine clearance should be confirmed to be at or above 80 ml/min. If creatinine clearance drops below 80 ml/min during treatment, fampridine must be discontinued. Regular monitoring of kidney function is recommended during ongoing treatment in patients over 65 years of age.
Missed Dose
If you forget to take a dose, do not take a double dose to make up for the missed one. Simply skip the missed dose and take the next tablet at your regular scheduled time, maintaining the 12-hour interval. Taking two tablets close together or at the same time is dangerous and significantly increases the risk of seizures. If you frequently forget doses, consider setting an alarm or using a pill organiser to help maintain your schedule.
Overdose
Overdose with fampridine is a medical emergency. Symptoms of overdose may include confusion, tremor, excessive sweating, seizures (convulsions), and in severe cases, status epilepticus (prolonged, uncontrolled seizures). If you suspect an overdose, call your local emergency number immediately or go to the nearest emergency department. There is no specific antidote. Treatment is supportive and may include activated charcoal (if within one hour of ingestion), benzodiazepines for seizures, and close monitoring of cardiac and respiratory function.
Clinical experience with fampridine overdose is limited, but reports indicate that seizures are the primary concern. The seizure threshold is dose-dependent, and plasma concentrations above the therapeutic range carry a substantial risk of provoking convulsions. In clinical trials, doses of 15 mg and 20 mg as single doses were associated with significantly higher rates of seizure activity compared to the recommended 10 mg dose.
What Are the Side Effects of Fampridin Medical Valley?
Like all medicines, Fampridin Medical Valley can cause side effects, although not everybody gets them. Most side effects are mild to moderate in severity and tend to diminish with continued treatment. However, some side effects are potentially serious and require immediate medical attention. The side effects are listed below according to their frequency of occurrence based on clinical trial data and post-marketing surveillance reports.
Very Common
Affects more than 1 in 10 patients
- Urinary tract infection
Common
Affects 1 to 10 in 100 patients
- Insomnia (difficulty sleeping)
- Anxiety
- Dizziness
- Headache
- Balance disorder
- Paraesthesia (tingling or numbness)
- Tremor
- Palpitations (awareness of heartbeat)
- Nausea
- Vomiting
- Constipation
- Dyspepsia (indigestion)
- Back pain
- Asthenia (weakness or fatigue)
Uncommon
Affects 1 to 10 in 1,000 patients
- Seizures (convulsions)
- Pharyngolaryngeal pain (sore throat)
- Dyspnoea (difficulty breathing)
- Rash
- Urticaria (hives)
- Neuralgia (nerve pain)
Rare / Post-Marketing Reports
Affects fewer than 1 in 1,000 patients
- Anaphylactic reaction (severe allergic reaction)
- Angioedema (swelling of face, lips, tongue, or throat)
- Status epilepticus (prolonged seizure)
- Trigeminal neuralgia (facial nerve pain)
Seizures are the most clinically significant adverse event associated with fampridine. The risk is dose-dependent and increases substantially at doses above 10 mg per administration. In clinical trials at the recommended dose of 10 mg twice daily, seizures occurred at a rate of approximately 0.41 per 100 patient-years. Although uncommon, seizures can occur without warning and may be severe. If you experience a seizure while taking fampridine, stop the medicine immediately and seek emergency medical care. Your doctor will determine whether the medicine should be permanently discontinued.
Anaphylactic reactions have been reported during post-marketing experience. These can include urticaria (hives), angioedema (swelling of the face, lips, tongue, or throat), and dyspnoea (difficulty breathing). Anaphylaxis can occur at any time during treatment, even in patients who have previously tolerated the medicine without problems. If you experience signs of a severe allergic reaction, stop taking fampridine and seek immediate medical attention.
Urinary tract infections (UTIs) are the most frequently reported adverse event. The mechanism by which fampridine increases UTI risk is not fully understood, but it may be related to changes in urinary function associated with MS. Patients should be aware of UTI symptoms (burning sensation during urination, frequent urination, cloudy or strong-smelling urine, lower abdominal pain) and seek prompt treatment if these develop.
If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed above. You can also report side effects directly to your national medicines regulatory authority (such as the EMA in Europe or FDA in the United States). By reporting side effects, you can help provide more information on the safety of this medicine.
How Should You Store Fampridin Medical Valley?
Proper storage of Fampridin Medical Valley is important to ensure the medicine remains effective and safe throughout its shelf life. The prolonged-release formulation relies on the integrity of the tablet coating to deliver fampridine at a controlled rate, and improper storage conditions could potentially compromise this mechanism.
- Temperature: Store below 25°C (77°F). Do not freeze. Brief exposure to temperatures above 25°C during transport is generally acceptable, but prolonged exposure to heat should be avoided.
- Light: Keep the tablets in the original packaging to protect from light. The blister packaging provides adequate light protection; do not transfer tablets to another container.
- Moisture: Store in a dry place. Do not store in the bathroom or kitchen where humidity levels are high. Keep the blister pack sealed until you are ready to take a tablet.
- Children: Keep this medicine out of the sight and reach of children. Accidental ingestion by children can cause serious adverse effects including seizures.
- Expiry date: Do not use this medicine after the expiry date stated on the carton and blister after "EXP." The expiry date refers to the last day of that month.
- Disposal: Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
If you notice any change in the appearance of the tablets (such as discolouration, crumbling, or an unusual odour), do not take them. Instead, return them to your pharmacist for safe disposal and obtain a replacement supply. Damaged tablets may not provide the correct prolonged-release profile, which could affect both efficacy and safety.
What Does Fampridin Medical Valley Contain?
Understanding the composition of your medicine can help you identify potential allergens and understand how the tablet works. The tablet is designed to release fampridine gradually over several hours, maintaining stable blood levels and reducing the risk of dose-related side effects.
Active Ingredient
- Fampridine (4-aminopyridine): 10 mg per tablet. This is the pharmacologically active substance that blocks potassium channels on demyelinated nerve fibres.
Inactive Ingredients (Excipients)
Tablet core:
- Hypromellose (HPMC): Forms the prolonged-release matrix that controls the rate of drug release from the tablet. This is the key excipient responsible for the modified-release properties of the formulation.
- Microcrystalline cellulose: A commonly used pharmaceutical filler and binder that provides structural integrity to the tablet.
- Colloidal anhydrous silica: A flow agent that improves the manufacturing process by preventing powder clumping.
- Magnesium stearate: A lubricant that prevents the tablet from sticking to manufacturing equipment during production.
Film coating:
- Hypromellose: Forms the film coat, which helps protect the tablet core and makes it easier to swallow.
- Titanium dioxide (E171): Provides the white colour of the tablet and protects the contents from light degradation.
- Macrogol (polyethylene glycol): Acts as a plasticiser in the film coat, ensuring the coating remains flexible and intact.
Tablet appearance: Fampridin Medical Valley 10 mg prolonged-release tablets are white to off-white, oval-shaped, biconvex, film-coated tablets. They may be marked with an identification code depending on the specific batch and manufacturing site.
If you have known allergies to any of the excipients listed above, inform your doctor or pharmacist before starting treatment. Although allergic reactions to these common pharmaceutical excipients are rare, it is important to disclose all known sensitivities.
Frequently Asked Questions About Fampridin Medical Valley
References
This article is based on the following peer-reviewed sources and international medical guidelines:
- European Medicines Agency (EMA). "Fampyra (fampridine) — Summary of Product Characteristics." EMA/CHMP. Last updated 2024. Available at: ema.europa.eu/fampyra
- Goodman AD, Brown TR, Krupp LB, et al. "Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial." The Lancet. 2009;373(9665):732-738. doi:10.1016/S0140-6736(09)60442-6
- Goodman AD, Brown TR, Edwards KR, et al. "A phase 3 trial of extended release oral dalfampridine in multiple sclerosis." Annals of Neurology. 2010;68(4):494-502. doi:10.1002/ana.22240
- U.S. Food and Drug Administration (FDA). "Ampyra (dalfampridine) — Prescribing Information." FDA. Last updated 2023. Available at: accessdata.fda.gov
- Hobart J, Blight AR, Goodman A, et al. "Timed 25-Foot Walk: Direct evidence that improving 20% or greater is clinically meaningful in MS." Neurology. 2013;80(16):1509-1517. doi:10.1212/WNL.0b013e31828cf7f3
- British National Formulary (BNF). "Fampridine." NICE. 2024. Available at: bnf.nice.org.uk
- Dunn J, Blight A. "Dalfampridine: a brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosis." Current Medical Research and Opinion. 2011;27(7):1415-1423. doi:10.1185/03007995.2011.583229
- World Health Organization (WHO). "ATC/DDD Index: N07XX07 — Fampridine." WHO Collaborating Centre for Drug Statistics Methodology. 2024.
- National Institute for Health and Care Excellence (NICE). "Fampridine for treating walking disability in people with multiple sclerosis (ID920)." NICE Technology Appraisal. 2023.
- Ruck T, Bittner S, Simon OJ, et al. "Long-term effects of dalfampridine in patients with multiple sclerosis." Journal of the Neurological Sciences. 2014;337(1-2):18-24. doi:10.1016/j.jns.2013.11.007
Editorial Team
Written by the iMedic Medical Editorial Team, specialists in neurology, pharmacology, and clinical medicine. All content follows the GRADE evidence framework and is reviewed by board-certified physicians.
Reviewed by the iMedic Medical Review Board — an independent panel of licensed physicians, neurologists, and clinical pharmacologists who verify medical accuracy according to EMA, FDA, and WHO guidelines.
iMedic follows strict editorial standards based on international medical guidelines. All medical claims are supported by Level 1A evidence (systematic reviews and meta-analyses of randomized controlled trials) where available. Content is reviewed and updated regularly to reflect the latest medical evidence. iMedic has no commercial funding and accepts no pharmaceutical company sponsorship. Read our full editorial standards.